Antiangiogenic drugs in non-small cell lung cancer treatment

Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108

Folkman, 1990, Endothelial cells and angiogenic growth factors in cancer growth and metastasis: introduction, Cancer Metastasis Rev, 9, 171, 10.1007/BF00046358

Hobson, 1984, Endothelial proliferation in tumours and normal tissues: continuous labelling studies, Br J Cancer, 4, 405, 10.1038/bjc.1984.66

Hyder, 1999, Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins, Mol Endocrinol, 6, 806, 10.1210/mend.13.6.0308

Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis [review], Cell, 3, 353, 10.1016/S0092-8674(00)80108-7

Risau, 1997, Mechanisms of angiogenesis [review], Nature, 6626, 671, 10.1038/386671a0

Forsythe, 1996, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, Moll Cell Biol, 16, 4604, 10.1128/MCB.16.9.4604

Takahashi, 1995, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Cancer Res, 18, 3964

Asahara, 1997, Isolation of putative progenitor endothelial cells for angiogenesis, Science, 5302, 964, 10.1126/science.275.5302.964

Gehling, 2000, In vitro differentiation of endothelial cells from AC133-positive progenitor cells, Blood, 10, 3106, 10.1182/blood.V95.10.3106

Benjamin, 1998, A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF, Development, 9, 1591, 10.1242/dev.125.9.1591

Benjamin, 1999, Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal, J Clin Invest, 2, 159, 10.1172/JCI5028

Carmeliet, 1999, Targeted deficiency or cytosolic truncation of the E-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis, Cell, 2, 147, 10.1016/S0092-8674(00)81010-7

Ferrara, 1992, Molecular and biological properties of the vascular endothelial growth factor family of proteins, Endocr Rev, 1, 18, 10.1210/edrv-13-1-18

Fontanini, 1997, Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma, Clin Cancer Res, 3, 861

Mattern, 1996, Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma, Br J Cancer, 73, 931, 10.1038/bjc.1996.166

Fontanini, 2002, A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma, Br J Cancer, 86, 558, 10.1038/sj.bjc.6600130

Delmotte, 2004, VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis [in French], Rev Mal Respir, 19, 577

Yuan, 2001, Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer, J Clin Oncol, 19, 432, 10.1200/JCO.2001.19.2.432

Han, 2001, Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis, Ann Surg Oncol, 8, 72, 10.1007/s10434-001-0072-y

Iwasaki, 2004, Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC, Eur J Cardiothorac Surg, 25, 443, 10.1016/j.ejcts.2003.11.031

Presta, 1997, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, Cancer Res, 57, 4593

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Wang, 2004, Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro, Angiogenesis, 4, 335, 10.1007/s10456-004-8272-2

Dvorak, 1995, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis, Am J Pathol, 5, 1029

Tortora, 2004, Angiogenesis: a target for cancer therapy, Curr Pharm Des, 10, 11, 10.2174/1381612043453595

Herbst, 2005, Angiogenesis and lung cancer: prognostic and therapeutic implications, J Clin Oncol, 23, 3243, 10.1200/JCO.2005.18.853

Johnson, 2005, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 11, 2184

Sandler, 2005, Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599 [abstract]., Proc Am Soc Clin Oncol, 24, 1090s

Raben, 2004, Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model, Mol Cancer Ther, 3, 977, 10.1158/1535-7163.977.3.8

Jung, 2002, Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model, Eur J Cancer, 38, 1133, 10.1016/S0959-8049(02)00013-8

Ciardiello, 2000, Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells, Clin Cancer Res, 6, 3739

Herbst, 2005, Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer, J Clin Oncol, 11, 2544, 10.1200/JCO.2005.02.477

Shepherd, 2002, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095

Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354

Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163

Hennequin, 2002, Novel 4- anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors, J Med Chem, 45, 1300, 10.1021/jm011022e

Wedge, 2002, ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration, Cancer Res, 62, 4645

Onn, 2003, Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice, Clin Cancer Res, 9, 5532

Wu, 2004, ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer, Proc Am Assoc Cancer Res, 45, 1051

Ciardiello, 2003, Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase, Clin Cancer Res, 9, 1546

Williams, 2003, Schedule-dependent effects of ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy in a lung tumor xenograft model, Clin Cancer Res, 9, 6141S

Hurwitz, 2002, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors [abstract], Proc Am Soc Clin Oncol, 21, 82a

Minami, 2003, A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors [abstract], Proc Am Soc Clin Oncol, 22, 194

Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer, J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038

Heymach, 2005, A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract]., Proc Am Soc Clin Oncol, 24, 3023, 10.1200/jco.2005.23.16_suppl.3023

Johnson, 2005, Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC [abstract]., Proc Am Soc Clin Oncol, 24, 7102, 10.1200/jco.2005.23.16_suppl.7102